Internal Medicine Unit, Cardiology Section, College of Medicine, Jouf University, Sakaka, Saudi Arabia.
Afr Health Sci. 2022 Sep;22(3):349-358. doi: 10.4314/ahs.v22i3.37.
The diagnostic significance of plasma soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) for non-ST segment elevated myocardial infarction (NSTEMI) and ST segment elevated myocardial infarction (STEMI) were explored by this study.
In this study, 107 acute NSTEMI, 223 acute STEMI and 107 healthy subjects, and hypoxic (1%02) ventricular cardiomyocytes H9c2 were used.
The significantly up-regulated plasma sLOX-1 levels in acute NSTEMI and STEMI patients compared to healthy subjects (p<0.001). Both male and female NSTEMI and STEMI groups had remarkably higher concentrations of plasma sLOX-1 levels than controls (p<0.001). The circulating levels of sLOX-1 expression obviously elevated in elderly aging (60-75 years) than younger aging (30-45 years) both male and female in healthy subjects as well as NSTEMI and STEMI (p<0.001). Altered levels of sLOX-1 in blood plasma revealed a significant discrimination with high sensitivity and specificity between healthy with NSTEMI and STEMI subjects with AUC= 0.916 and AUC= 0.925 respectively. Moreover, LOX-1 levls were highly released from 6hour, 12hour and 18hour hypoxic injured H9c2 cells than normoxic cell (p<0.001), reflected circulating plasma sLOX-1 in AMI patients.
Elevated levels of plasma sLOX-1concentrations might be used as a clinical biomarker for early recognition of NSTEMI and STEMI patients. Multicenter larger scale studies are necessary before use in clinical practice.
本研究旨在探讨血浆可溶性凝集素样氧化低密度脂蛋白受体-1（sLOX-1）对非 ST 段抬高型心肌梗死（NSTEMI）和 ST 段抬高型心肌梗死（STEMI）的诊断意义。
本研究纳入了 107 例急性 NSTEMI 患者、223 例急性 STEMI 患者和 107 例健康对照者，并使用低氧（1%O2）培养的心室肌细胞 H9c2 进行实验。
与健康对照组相比，急性 NSTEMI 和 STEMI 患者的血浆 sLOX-1 水平显著升高（p<0.001）。NSTEMI 和 STEMI 患者中，男性和女性患者的血浆 sLOX-1 水平均显著高于对照组（p<0.001）。在健康对照者以及 NSTEMI 和 STEMI 患者中，与年轻年龄（30-45 岁）相比，老年年龄（60-75 岁）的血浆 sLOX-1 表达水平明显升高（p<0.001）。sLOX-1 在血液中的水平变化在健康对照者与 NSTEMI 和 STEMI 患者之间具有显著的区分度，其 AUC 分别为 0.916 和 0.925，具有较高的灵敏度和特异性。此外，与常氧细胞相比，低氧损伤的 H9c2 细胞在 6 小时、12 小时和 18 小时时释放出更高水平的 LOX-1（p<0.001），这反映了 AMI 患者循环血浆 sLOX-1 的情况。
血浆 sLOX-1 浓度的升高可能作为识别 NSTEMI 和 STEMI 患者的临床生物标志物。在临床实践中应用之前，还需要进行更大规模的多中心研究。
